The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia

Reviews in the Neurosciences

Volumn 25, Issue 3, 2014, Pages 367-382

  Nikiforuk, Agnieszka ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT6 receptor; Cognition; Executive functions; NMDA receptor; Therapeutics

Indexed keywords

5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; EMD 386088; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PRX 07034; RO 4368554; SB 258585; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; LIGAND; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATTENTION; COGNITIVE DEFECT; EXECUTIVE FUNCTION; LEARNING; NONHUMAN; RECOGNITION; REVIEW; SCHIZOPHRENIA; SOCIAL COGNITION; TASK PERFORMANCE; WORKING MEMORY; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 84907170087     PISSN: 03341763     EISSN: 21910200     Source Type: Journal    
DOI: 10.1515/revneuro-2014-0005     Document Type: Review

References (134)

1. Antunes M. and Biala G. (2012). The novel object recognition memory: neurobiology test procedure and its modifications. Cogn. Process 13 93-110
2. Arnt J. and Olsen C.K. (2011). 5-HT6 receptor ligands and their antipsychotic potential. In t. Rev. Neurobiol. 96 141-161
3. Arnt J. and Skarsfeldt T. (1998). Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 18 63-101
4. Arnt J. Bang-Andersen B. Grayson B. Bymaster F.P. Cohen M.P. DeLapp N.W. Giethlen B. Kreilgaard M. McKinzie D.L. Neill J.C. et al. (2010). Lu AE58054 a 5-HT6 antagonist re verses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol. 13 1021-1033
5. Bari A. Dalley J.W. and Robbins T.W. (2008). The appl ication of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat. Protoc. 3 759-767
6. Birrell J.M. and Brown V.J. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20 4320-4324
7. Bissonette G.B. and Powell E.M. (2012). Reversal learning and attentional set-shifting in mice. Neuropharmacology 62 1168-1174
8. Braff D.L. (1993). Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 19 233-259
9. Braff D.L. and Light G.A. (2004). Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl) 174 75-85.
10. Broberg B.V.,Dias R.,Glenthoj B.Y.,Olsen C.K., 2008, Evaluation of a neurodevelopmental model of schizophrenia-Early postnatal PCP treatment in attentional set-shifting, Behav. Brain Res., 190, 160-163
11. Broberg B.V. Glenthoj B.Y. Dias R. Larsen D.B. and Olsen C.K. (2009). Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia-subchronic and early postnatal PCP treatment in attentional set-shifting. Psychophar macology (Berl) 206 631-640
12. Buckley P.F. Miller B.J. Lehrer D.S. and Castle D.J. (2009). Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 35 383-402
13. Burnha m K.E. Baxter M.G. Bainton J.R. Southam E. Dawson L.A. Bannerman D.M. and Sharp T. (2010). Activation of 5-HT(6) receptors facilitates attentional set shifting. Psychopharmacology (Berl) 208 13-21
14. Carr G.V. Schechter L.E. and Lucki I. (2011). Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacology (Berl) 213 499-507
15. Chuang A.T.T. Foley A. Pugh P.L. Sunter D. Tong X Regan C. and Dawson L.A. (2006). 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer's disease. Alzheimer's Dementia 2 S631-S632
16. Cochran S.M. Kennedy M. McKerchar C.E. Steward L.J. Pratt J.A. and Morris B.J. (2003). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: d ifferential modulation by antipsychotic drugs. Neuropsychopharmacology 28 265-275
17. Codony X. Burgueno J. Ramirez M.J. and Vela J.M. (2010). 5-HT6 receptor signal transduction second messenger systems. Int. Rev. Neurobiol. 94 89-110
18. Couture S.M. Penn D.L. and Roberts D.L. (2006). The functional significance of social cognition in schizophrenia: a review. Schizophr. Bull. 32 (Suppl 1) S44-S63
19. Da Silva Costa-Aze V. Dauphin F. and Boulouard M. (2011). Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice. Behav. Brain Res. 222 134-140
20. Da Silva Costa-Aze V. Quiedeville A. Boulouard M. and Dauphin F. (2012). 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory recognition memory and aversive learning in mice. Psychopharmacology (Berl) 222 99-115
21. Damgaard T. Larsen D.B. Hansen S.L. Grayson B. Neill J.C. and Plath N. (2010). Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepro pionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav. Brain Res. 207 144-150.
22. Dawson L.A. (2011). The central role of 5-HT6 receptors in modulating brain neurochemistry. Int. Rev. Neurobiol. 96 1-26
23. Dawson L.A. Nguyen H.Q. and Li P. (2000). In vivo effects of the 5-H T(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline dopamine 5-HT glutamate and aspartate. Br. J. Pharmacol. 130 23-26
24. Dawson L.A. Nguyen H.Q. and Li P. ( 2001). The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 662-668
25. Dawson N. Thompson R.J. McVie A. Thomson D.M. Morris B.J. and Pratt J.A. (2012). Modafinil reverses phencyclidineinduced deficits in cognitive flexibility cerebral metabolism and functional brain connectivity. Schizophr. Bull. 38 457-474
26. de Bruin N.M. McCreary A.C. van Loevezijn A. de Vries T.J. Venhorst J. van Drimmelen M. and Kruse C.G. (2013a). A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seek ing but does not affect inhibitory response control in Wistar rats. Behav. Brain Res. 236 157-165
27. de Bruin N.M. van Drimmelen M. Kops M. van Elk J. Middelveld-van de Wetering M. and Schwienbacher I. (2013b). Effects of risperidone clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats. Behav. Brain Res. 244 15-28
28. Didrik sen M. Skarsfeldt T. and Arnt J. (2007). Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 193 225-233
29. D udchenko P.A. Wood E.R. and Eichenbaum H. (2000). Neurotoxic hippocampal lesions have no effect on odor span and little effect on odor recognition memory but produce significant impairments on spatial span recognition and alternatio n. J. Neurosci. 20 2964-2977
30. Dudchenko P.A. Talpos J. Young J. and Baxter M.G. (2013). Animal models of working memory: A review of tasks that might be used in screening drug treatments for the mem ory impairments found in schizophrenia. Neurosci. Biobehav. Rev. 37 2111-2124.
31. Eisenberg D.P.,Berman K.F. (2010), Executive function neural circuitry and genetic mechanisms in schizophrenia, Neuropsychopharmacology, 35, 258-277
32. Elvevag B. and Goldberg T.E. (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev. Neurobiol. 14 1-21
33. Engelmann M. Wotjak C.T. and Landgraf R. (1995). Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol Behav. 58 315-321
34. Ennaceur A. and Delacour J. (1988). A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 31 47-59
35. Fijal K. Popik P. and Nikiforuk A. (2014). Co-administration of 5-HT6 receptor antagonists with clozapine risperidone and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats. Psychopharmacology (Berl) 231 269-281
36. Foley A.G. Murphy K.J. Hirst W.D. Gallagher H.C. Hagan J.J. Upton N. Walsh F.S. and Regan C.M. (2004). The 5-HT(6) receptor antagonist SB-271046 reverses scopolaminedisrupted consolidation of a p assive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 29 93-100
37. Foley A.G. Hirst W.D. Gallagher H.C. Barry C. Hagan J.J. Upton N. Walsh F.S. Hunter A.J. and Regan C.M. (2008). The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells but not neurogenesis in the hippocampal formation of mature Wistar rats. Neuropharmacology 54 1166-1174
38. Fone K.C. (2008). An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55 1015-1022
39. Gilmour G. Arguello A. Bari A. Brown V.J. Carter C. Floresco S.B. Jentsch D.J. Tait D.S. Young J.W. and Robbins T.W. (2013). Measuring the construct of executive control in schizophrenia: Defining and validati ng translational animal paradigms for discovery research. Neurosci. Biobehav. Rev. 37 2125-2140
40. Goetghebeur P. and Dias R. (2009). Comparison of haloperidol risperidone sertindole and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-A back translational study. Psychopharmacology (Berl). 202 287-293
41. Gold J.M. Hahn B. Zhang W.W. Robinson B.M. Kappenman E.S. Beck V.M. and Luck S.J. (2010). Reduced capacity but spared precision and maintenance of working memory representations in schizophrenia. Arch. Gen. Psychiatry 67 570-577
42. Gravius A. Laszy J. Pietraszek M. Saghy K. Nagel J. Chambon C. Wegener N. Valastro B. Danysz W. and Gyertyan I. (2011). Effects of 5-HT6 antagonists Ro-4368554 and SB-258585 in tests used for the detection of cogniti ve enhancement and antipsychotic-like activity. Behav. Pharmacol. 22 122-135
43. Green M.F. Kern R.S. and Heaton R.K. (2004). Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72 41-51
44. Harvey P.D. and Keefe R.S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158 176-184
45. Hatcher P.D. Brown V.J. Tait D.S. Bate S. Overend P. Hagan J.J. and Jones D.N. (2005). 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats . Psychopharmacology (Berl) 181 253-259
46. Heal D. Gosden J. and Smith S. (2011). The 5-HT6 receptor as a target for developing novel antiobesity drugs. Int. Rev. Neurobiol. 96 73-109
47. Heal D.J. Smith S.L. Fisas A. Codony X. and Buschmann H. (2008). Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic d isorders. Pharmacol. Ther. 117 207-231
48. Hirst W.D. Moss S.F. Bromidge S.M. Riley G. Stean T.O. Rogers D.C. Sunter D. Lacroix L.P. Atkins A.R. Dawson L.A. and Upton N. (2003 a ). Characterisation of SB-399885 a potent and selective 5-HT6 receptorantagonist. Society for Neuroscience Abstracts 576.7
49. Hirst W.D. Abrahamsen B. Blaney F.E. Calver A.R. Aloj L. Price G.W. and Medhurst A.D. (2003b ). Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding site-directed mutagenesis a nd molecular modeling. Mol. Pharmacol. 64 1295-1308
50. Hirst W.D. Stea n T.O. Rogers D.C. Sunter D. Pugh P. Moss S.F. Bromidge S.M. Riley G. Smith D.R. Bartlett S. et al. (2006). SB-399885 is a potent selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 553 109-119
51. Hughes R.N. (2004). The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 28 497-505.
52. Idris N.,Neill J.,Grayson B.,Bang-Andersen B.,Witten L.M.,Brennum L.T.,Arnt J.,(2010). Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl), 208, 23-36
53. Jentsch J.D. Redmond D.E. Jr. Elsworth J.D. Taylor J.R. Youngren K.D. and Roth R.H. (1997). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277 953-955
54. Jones C.A. Watson D.J. and Fone K.C. (2011). Animal models of schizophrenia. Br. J. Pharmacol. 164 1162-1194
55. Karper L.P. Freeman G.K. Grillon C. Morgan C.A. III Charney D.S. and Krystal J.H. (1996). Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. J. Neuropsychiatry Clin. Neurosci. 8 60-66
56. Keeler J.F. and Robbins T.W. ( 2011). Translating cognition from animals to humans. Biochem. Pharmacol. 81 1356-1366
57. Kendall I. Slotten H.A. Codony X. Burgueno J. Pauwels P.J. Vela J.M. and Fone K.C. (2011). E-6801 a 5-HT6 receptor agonist improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 213 413-430
58. King M.V. Sleight A.J. Woolley M.L . Topham I.A. Marsden C.A. and Fone K.C. (2004). 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuropha rmacology 47 195-204
59. King M. Fone K.F. Shacham S. and Gannon K.S. (2007). PRX-07034 a 5-HT6 antagonist reduces weight gain and enhances memory in a neurodevelopmental model of schizophrenia. Society for Neuroscience Abstracts 499.25
60. Kos T. Nikiforuk A. Rafa D. and Popik P. (2011). The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice. Psychopharmacology (Berl) 214 911-921
61. Krystal J.H. Karper L.P. Seibyl J.P. Freeman G.K. Delaney R. Bremner J.D. Heninger G.R. Bowers M.B. Jr. and Charney D.S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans. Psychotomimetic perceptual cognitive and neuroendocrine responses. Arch. Gen. Psychiatry 51 199-214
62. Lacroix L.P. Dawson L.A. Hagan J.J. and Heidbreder C.A. (2004). 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51 158-164
63. Leng A. Ouagazzal A. Feldon J. and Higgins G.A. (2003). Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol. Biochem. Behav. 75 281-288
64. Lesem M. (2007). A ra ndomized placebo-controlled phase IIa trial of sgs518 for treating cognitive impairment associated with schizophrenia. Schizophrenia Bulletin 33 441
65. Lewis D.A. and Gonzalez-Burgos G. (2008). Neuroplasticit y of neocortical circuits in schizophrenia. Neuropsychopharmacology 33 141-165
66. Li Z. Huang M. Prus A.J. Dai J. and Meltzer H.Y. (2007). 5-HT6 receptor antagonist SB-399885 potentiates hal operidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 1134 70-78
67. Lisman J.E. Coyle J.T. Green R.W. Javitt D.C. Benes F.M. Heckers S. and Grace A.A. (2008). Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31 234-242
68. Liy-Salmeron G. and Meneses A. (2008). Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model. Hippocampus 18 965-974
69. Loiseau F. Dekeyne A. and Millan M.J. (2008). Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 196 93-104
70. Lundbeck (2008). Study ID: 12450A. ClinicalTrials.gov Identifier: 00810667. Title: Efficacy study exploring the effect of Lu AE58054 as augmentation therapy in patients with schizophrenia
71. Marcos B. Chuang T.T. Gil-Bea F.J. and Ramirez M.J. (2008). Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br. J. Pharmacol. 155 434-440
72. Marcos B. Gil-Bea F.J. Hirst W.D. Garcia-Alloza M. and Ramirez M.J. (2006). Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur. J. Neurosci. 24 1299-1306
73. McLean S.L. Beck J.P. Wo olley M.L. and Neill J.C. (2008). A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav. Brain Res. 189 152-158.
74. Meffre J.,Chaumont-Dubel S.,Mannoury la C.C.,Loiseau F.,Watson D.J.,Dekeyne A.,Seveno M.,Rivet J.M.,Gaven F.,Deleris P.,et al., (2012). 5-HT(6) receptor recruitment of mTOR as a mechani sm for perturbed cognition in schizophrenia. EMBO Mol. Med., 4, 1043-1056
75. Meltzer H.Y. Horiguchi M. and Massey B.W. (2011). The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213 289-305
76. Meneses A. (2001). Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation. Behav. Brain Res. 118 107-110
77. Meneses A. Perez-Garcia G. Liy-Salmeron G. Flores-Galvez D. Castillo C. and Castillo E. (2008). The effects of the 5-HT(6) receptor agonist EMD and the 5-HT(7) receptor agonist AS19 on memory forma tion. Behav. Brain Res. 195 112-119
78. Meneses A. Perez-Garcia G. Ponce-Lopez T. and Castillo C. (2011). 5-HT6 receptor memory and amnesia: behavioral pharmacology-learning and memory processes. Int. Rev. Neurobiol. 96 27-47
79. Mitchell E.S. (2011). 5-HT6 receptor ligands as antidementia drugs. Int. Rev. Neurobiol. 96 163-187
80. Mitchell E.S. and Neumaier J.F. (2008). 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine. Pharmacol. Biochem. Behav. 88 291-298
81. Moghaddam B. and Adams B.W. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 1349-1352
82. Mohler E.G. Baker P.M. Gannon K.S. Jones S.S. Shacham S. Sweeney J.A. and Ragozzino M.E. (2012). The effects of PRX-07034 a novel 5-HT6 antagonist on cognitive flexibility and working memory in rats. Psychopharmacology ( Berl) 220 687-696
83. Monsma F.J. Shen Y. Ward R.P. Hamblin M.W. and Sibley D.R. (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 43 320-327
84. Moore H. Geyer M.A. Carter C.S. and Barch D.M. (2013). Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selecte d cognitive paradigms for animal models. Neurosci. Biobehav. Rev. 37 2087-2091
85. Mork A. Witten L.M. and Arnt J. (2009). Effect of sertindole on extracellular dopamine acetylcholine and glutamate in the m edial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl) 206 39-49
86. Morozova M.A. Beniashvili A.G. Lepilkina T.A. and Rupc hev G.E. (2012). Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr. Danub. 24 159-166
87. Murray G.K. Cheng F. Clark L. Barnett J.H. Blackwell A.D. Fletcher P.C. Robbins T.W. Bullmore E.T. and Jones P.B. (2008). Reinforcement and reversal learning in first-episode psychosi s. Schizophr. Bull. 34 848-855
88. Nakazawa K. Zsiros V. Jiang Z. Nakao K. Kolata S. Zhang S. and Belforte J.E. (2012). GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62 1574-1583
89. Neill J.C. Barnes S. Cook S. Grayson B. Idris N.F. McLean S.L. Snigdha S. Rajagopal L. and Harte M.K. (2010). Animal models of cognitive dysf unction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. 128 419-432
90. Nikiforuk A. and Popik P. (2012). Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology (Berl) 220 65-74
91. Nikiforuk A. Golembiowska K. and Popik P. (2010). Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur. Neuropsychopharmacol. 20 37-48
92. Nikiforuk A. Kos T. Rafa D. Behl B. Bespalov A. and Popik P. (2011a). Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptordependent manner. Neuropharmacology 61 262-267
93. Nikiforuk A. Kos T. and Wesolo wska A. (2011b). The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. Psychopharmacology (Berl) 217 411-418
94. Nikiforuk A. Fijal K. Potasiewicz A. Popik P. and Kos T. (2013). The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition but not in the prepulse inh ibition in rats. J. Psychopharmacol. 27 469-476.
95. Nuechterlein K.H.,Barch D.M.,Gold J.M.,Goldberg T.E.,Green M.F.,Heaton R.K., 2004, Identification of separable cognitive factors in schizophrenia. Schizophr. Res., 72, 29-39
96. Nyhus E. and Barcelo F. (2009). The Wisconsin Card Sorting Test and the cognitive assessment of prefrontal executive functions: a critical update. Brain Cogn 71 437-451
97. Orellana G. and Slachevsky A. (2013). Executive functioning in schizophrenia. Front Psychiatry 4 35
98. Pelletier M. Achim A.M. Montoya A. Lal S. and Lepage M. (2005). Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr. Res. 74 233-252
99. Perez-Garcia G. and Meneses A. (2005). Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol. Biochem. Behav. 81 673-682
100. Pitsikas N. Zisopoulou S. Pappas I. and Sakellaridis N. (2008). The selective 5-HT(6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. Behav. Brain Res. 188 304-309
101. Polgar P. Farkas M. Nagy O. Kelemen O. Rethelyi J. Bitter I. Myers C.E. Gluck M.A. and Keri S. (2008). How to find the way out from four rooms? The learning of ?chaining' associations ma y shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophr. Res. 99 200-207
102. Pouzet B. Didriksen M. and Arnt J. (2002). Effects of the 5-HT(6) receptor antagonist SB-271046 in animal models for schizophrenia. Pharmacol. Biochem. Behav. 71 635-643
103. Rajagopal L. Massey B.W. Huang M. Oyamada Y. and Meltzer H.Y. (2013). The Novel Object Recogniton Test in Rodents in R elation to Cognitive Impairment in Schizophrenia. Curr. Pharm. Des. PMID: 24345269 [Epub ahead of print]
104. Riemer C. Borroni E. Levet-Trafit B. Martin J.R. Poli S. Porter R.H. and Bos M. (2003). Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine a potent and selective 5-HT6 receptor antagonist. J. Med. Chem. 46 1 273-1276
105. Roberts A.C. Robbins T.W. and Everitt B.J. (1988). The effects of intradimensional and extradimensional shifts on visual discrimination learning in humans and non-human primates. Q. J. Exp. Psychol. B 40 321-341
106. Rodefer J.S. Nguyen T.N. Karlsson J.J. and Arnt J. (2008). Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33 2657-2666
107. Ruat M. Traiffort E. Arrang J.M. Tardivel-Lacombe J. Diaz J. Leurs R. and Schwartz J.C. (1993). A novel rat serotonin (5-HT6) receptor: molecular cloning localization and stimulation of cAMP accumulatio n. Biochem. Biophys. Res Commun. 193 268-276
108. Sams-Dodd F. (1999). Phencyclidine in the social interaction test: An animal model of shizophrenia with face and predictive validity. Reviews in Neurosciences 10 59-89
109. Sarter M. Lustig C. and Taylor S.F. (2012). Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology 62 1544-1553
110. Schaffhauser H. Mathiasen J.R. DiCamillo A. Huffman M.J. Lu L.D. McKenna B.A. Qian J. and Marino M.J. (2009). Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. B iochem. Pharmacol. 78 1035-1042
111. Schechter L.E. Lin Q. Smith D.L. Zhang G. Shan Q. Platt B. Brandt M.R. Dawson L.A. Cole D. Bernotas R. et al. (2008). Neuroph armacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33 1323-1335
112. Schreiber R. Vivian J. Hedley L. Szczepanski K. Secchi R.L. Zuzow M. van L.S. Moreau J.L. Martin J.R. Sik A. et al. (2007). Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 17 277-288
113. Shirazi-Southall S. Rodriguez D.E. and Nomikos G.G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 583-594
114. Stean T.O. Hirst W.D. Thomas D.R. Price G.W. Rogers D. Riley G. Bromidge S.M. Serafinowska H.T. Smith D.R. Bartlett S. et al. (2002). Pharmacological profile of SB-357134: a potent selective brain penetrant and orally active 5-HT(6) receptor antagonist. Pharmacol. Biochem. Behav. 71 645-654
115. Svenningsson P. Tzavara E.T. Qi H. Carruthers R. Witkin J.M. Nomikos G.G. and Greengard P. (2007). Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J. Neurosci. 27 4201-4209.
116. Swerdlow N.R.,Braff D.L.,Geyer M.A., 2000, Animal models of deficient sensorimotor gating: what we know what we think we know and what we hope to know soon. Behav. Pharmacol., 11, 185-204
117. Tait D.S. Chase E.A. and Brown V.J. (2013). Attentional Set-Shifting in Rodents: a Review of Behavioural Methods and Pharmacological Results. Curr. Pharm. Des. PMID: 24345263 [Epub ahead of print]
118. Talpos J.C. Wilkinson L.S. and Robbins T.W. (2006). A comparison of multiple 5-HT receptors in two tasks measuring impulsivity. J. Psychopharmacol. 20 47-58
119. Tassone A. Madeo G. Schirinzi T. Vita D. Puglisi F. Ponterio G. Borsini F. Pisani A. and Bonsi P. (2011). Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. Neuropharmacology 61 632-637
120. Thor D.H. and Holloway W.R. (1982). Social memory of the male laboratory rat. Journal of Comparative and Physiological Psychology 96 1000-1006
121. Tripathy R. McHugh R.J. Bacon E.R. Salvino J.M. Morto n G.C. Aimone L.D. Huang Z. Mathiasen J.R. DiCamillo A. Huffman M.J. et al. (2012). Discovery of 7-arylsulfonyl-1234 4a9a-hexahydro-benzo[45]furo[23-c]pyridines: identification of a potent and selective 5-HT (6) receptor antagonist showing activity in rat social recognition test. Bioorg. Med. Chem. Lett. 22 1421-1426
122. Upton N. Chuang T.T. Hunter A.J. and Virley D.J. (2008). 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 5 458-469
123. Valentini V. Frau R. Bordi F. Borsini F. and Di C.G. (2011). A microdialysis study of ST1936 a novel 5-HT6 receptor agonist. Neuropharmacology 60 602-608
124. van der Zwaal E.M. Janhunen S.K. la Fleur S.E. and Adan R.A. (2013). Modelling olanzapine-induced weight gain in rats. Int. J. Neuropsychopharmacol. 17 1-18
125. Wesolowska A. and Jastrzebska-Wiesek M. (2011). Behavioral pharmacology: potential antidepressant and anxiolytic properties. Int. Rev. Neurobiol. 96 49-71
126. Wesolowska A. and Nikiforuk A. (2007). Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 52 1274-1283
127. West P.J. Marcy V.R. Marino M.J. and Schaffhauser H. (2009). Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 164 692-701
128. Woods S. Clarke N.N. Layfield R. and Fone K.C. (2012). 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradig m by modulation of cholinergic and glutamatergic mechanisms. Br. J. Pharmacol. 167 436-449
129. Woolley M.L. Bentley J.C. Sleight A.J. Marsden C.A. and Fone K.C. (2001). A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology. 41 210-219
130. Woolley M.L. Marsden C.A. and Fone K.C. (2004). 5-ht6 receptors. Curr. Drug Targets. CNS. Neurol. Disord. 3 59-79
131. Young J.W. Powell S.B. Risbrough V. Marston H.M. and Geyer M.A. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122 150-202
132. Young J.W. Zhou X. and Geyer M.A. (2010). Animal models of schizophrenia. Curr. Top. Behav. Neurosci. 4 391-433
133. Yun H.M. Kim S. Kim H.J. Kostenis E. Kim J.I. Seong J.Y. Baik J.H. and Rhim H. (2007). The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J. Biol. Chem. 282 5496-5505
134. Zhang M.Y. Hughes Z.A. Kerns E.H. Lin Q. and Beyer C.E. (2007). Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain m icrodialysis samples. J. Pharm. Biomed. Anal. 44 586-593